Modulators of the ghrelin system as potential treatments for obesity and diabetes

Expert Opinion on Therapeutic Patents

Volumn 18, Issue 11, 2008, Pages 1253-1263

  Carpino, Philip A ^a   Ho, Guyu ^a  

^a PFIZER INC   (United States)

Author keywords

Antibodies; Antibody catalysts; Catalytic activating antibodies; Diabetes; Ghrelin; Ghrelin O acyltransferase; Ghrelin receptor antagonists; Ghrelin secretion inhibitors; GHS R1a antagonists; Growth hormone; Monoclonal antibodies; Non peptidyl GhR antagonists; Obesity; Peptidyl GhR antagonists; Spiegelmers; Vaccines

Indexed keywords

1,2,4 OXADIAZOLYL DERIVATIVE; 2 AMINO 2 METHYLPROPIONIC ACID; 2 OXO 2,3,4,5 TETRAHYDRO 1H BENZ[B]AZEPINE DERIVATIVE; A 778193; ANTIBODY CONJUGATE; ANTIOBESITY AGENT; CAPROMORELIN; CATALYTIC ANTIBODY; CORTISTATIN; DIAZEPINE 2,5 DIONE DERIVATIVE; GHRELIN; GHRELIN ANTIBODY; GHRELIN BOVINE SERUM ALBUMIN ANTIBODY CONJUGATE; GHRELIN INHIBITOR; GHRELIN KEYHOLE LIMPET HEMOCYANIN ANTIBODY CONJUGATE; GROWTH HORMONE SECRETAGOGUE RECEPTOR ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; IBUTAMOREN; ISOXAZOLE DERIVATIVE; L 692400; LXG 924; MONOCLONAL ANTIBODY; PRAMLINTIDE; PYRAZOLYL DERIVATIVE; QUINAZOLINONE DERIVATIVE; SPIEGELMER; SULFONAMIDE; TABIMORELIN; TETRALIN DERIVATIVE; TM 27810; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DECREASED APPETITE; DIABETES MELLITUS; DRUG MECHANISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; ENERGY METABOLISM; FOOD INTAKE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; NONHUMAN; OBESITY; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION; VACCINATION; WEIGHT REDUCTION;

EID: 56849115949     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.18.11.1253     Document Type: Review

References (86)

1. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-60
2. Yang J, Brown MS, Liang G, et al. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 2008;132:387-96
3. Gutierrez JA, Solenberg PJ, Perkins DR, et al. Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci USA 2008;105:6320-5
4. Broglio F, Gotrero C, Prodam F, et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab 2004;89:3062-5
5. Gauna C, Meyler FM, Janssen JA, et al. Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab 2004;89:5035-42
6. Hosoda H, Kojima M, Matsuo H, et al. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 2000;279:909-13
7. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996;273:974-7
8. Carpino PA. Recent developments in ghrelin receptor (GHS-R1a) agonists and antagonists. Expert Opinion on Therapeutic Patents 2002;12:1599-618
9. McKee KK, Palyha OC, Feighner SD, et al. Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. Mol Endocrinol 1997;11:415-23
10. Dezaki K, Kakei M, Yada T. Ghrelin uses Galphai2 and activates voltage-dependent K+ channels to attenuate glucose-induced Ca2+ signaling and insulin release in islet beta-cells: novel signal transduction of ghrelin. Diabetes 2007;56:2319-27
11. Holst B, Cygankiewicz A, Jensen TH, et al. High constitutive signaling of the ghrelin receptor - identification of a potent inverse agonist. Mol Endocrinol 2003;17:2201-10
12. Zigman JM, Jones JE, Lee CE, et al. Expression of ghrelin receptor mRNA in the rat and the mouse brain. J Comp Neurol 2006;494:528-48
13. Baldanzi G, Filigheddu N, Cutrupi S, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/ 2 and PI 3-kinase/AKT. J Cell Biol 2002;159:1029-37
14. Popovic V, Miljic D, Micic D, et al. Ghrelin main action on the regulation of growth hormone release is exerted at hypothalamic level. J Clin Endocrinol Metab 2003;88:3450-3
15. Okimura Y, Ukai K, Hosoda H, et al. The role of circulating ghrelin in growth hormone (GH) secretion in freely moving male rats. Life Sci 2003;72:2517-24
16. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000;407:908-13
17. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001;409:194-8
18. Wren AM, Smalll CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000;141:4325-8
19. Dezaki K, Sone H, Yada T. Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol Ther 2008; 118:239-49
20. Sun Y, Asnicar M, Smith RG. Central and peripheral roles of ghrelin on glucose homeostasis. Neuroendocrinology 2007;86:215-28
21. Wiedmer P, Nogueiras R, Broglio F, et al. Ghrelin, obesity and diabetes. Nat Clin Pract Endocrinol Metab 2007;3:705-12
22. Pusztai P, Sarman B, Ruzicska E, et al. Ghrelin: a new peptide regulating the neurohormonal system, energy homeostasis and glucose metabolism. Diabetes Metab Res Rev 2008;24:343-52
23. Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001;50:1714-9
24. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623-30
25. Asakawa A, Inui A, Kaga T, et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 2003;52:947-52
26. Tschop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001;50:707-9
27. Shuto Y, Shibasaki T, Otagiri A, et al. Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J Clin Invest 2002;109:1429-36
28. Zigman JM, Nakano Y, Coppari R, et al. Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 2005;115:3564-72
29. Wortley KE, Anderson KD, Garcia K, et al. Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci USA 2004;101:8227-32
30. Wortley KE, del Rincon JP, Murray JD, et al. Absence of ghrelin protects against early-onset obesity. J Clin Invest 2005;115:3573-8
31. Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001;50:227-32
32. Date Y, Nakazato M, Hashiguchi S, et al. Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes 2002;51:124-9
33. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002;87:2988
34. Wierup N, Svensson H, Mulder H, et al. The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas. Regul Pept 2002;107:63-9
35. Dezaki K, Hosoda H, Kakei M, et al. Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2+ signaling in beta-cells: implication in the glycemic control in rodents. Diabetes 2004;53:3142-51
36. Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001;86:5083-6
37. Egido EM, Rodriguez-Gallardo J, Silvestre RA, et al. Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion. Eur J Endocrinol 2002;146:241-4
38. Sun Y, Asnicar M, Saha PK, et al. Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab 2006;3:379-86
39. Longo KA, Charoenthongtrakul S, Giuliana DJ, et al. Improved insulin sensitivity and metabolic flexibility in ghrelin receptor knockout mice. Regul Pept 2008
40. Lee HM, Wang G, Englander EW, et al. Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology 2002;143:185-90
41. Salehi A, Dornonville de la Cour C, Hakanson R, et al. Effects of ghrelin on insulin and glucagon secretion: a study of isolated pancreatic islets and intact mice. Regul Pept 2004;118:143-50
42. Veeraragavan K, Sethumadhavan K, Bowers CY. Growth hormone-releasing peptide (GHRP) binding to porcine anterior pituitary and hypothalamic membranes. Life Sci 1992;50:1149-55
43. Zentaris A-G., Germany. Ghrelin antagonist peptides. WO2002008250; 2002
44. Ardana Bioscience Limited, UK. Cortistatin analogs selective binding to growth hormone secretagogue receptors and uses in treatment of tumors, acromegaly and reduction of the appetite. WO2003004518; 2003
45. Deghenghi R, Broglio F, Papotti M, et al. Targeting the ghrelin receptor: orally active GHS and cortistatin analogs. Endocrine 2003;22:13-8
46. Novo Nordisk A/S, Den. Use of ghrelin antagonists for therapy of CNS diseases. WO2005112903; 2005
47. The Administrators of the Tulane Educational Fund, USA. Ghrelin/growth hormone releasing peptide/growth hormone secretagogue receptor antagonists and uses thereof. WO2007127457; 2007
48. Societe de Conseils de Recherches et d'Applications Scientifiques S.A.S., Fr. Preparation of therapeutic analogs of ghrelin active at the GHS receptor. WO2007038678; 2007
49. Societe de Conseils de Recherches et d'Applications Scientifiques S.a.S., Fr. Analogs of ghrelin substituted at the N-terminal for improved plasma stability and modulation of receptor activity. WO2008039415; 2008
50. Cheng K, Chan WW, Butler B, et al. Stimulation of growth hormone release from rat primary pituitary cells by L-692,429, a novel non-peptidyl GH secretagogue. Endocrinology 1993;132:2729-31
51. 7TM Pharma A/S, Den. Ghrelin receptor inverse agonists for regulation of feeding behaviors. WO2004056869; 2004
52. Liu B, Liu G, Xin Z, et al. Novel isoxazole carboxamides as growth hormone secretagogue receptor (GHS-R) antagonists. Bioorg Med Chem Lett 2004;14:5223-6
53. Zhao H, Liu G. Growth hormone secretagogue receptor antagonists as anti-obesity therapies? Still an open question. Curr Opin Drug Discov Devel 2006;9:509-15
54. Zhao H, Xin Z, Liu G, et al. Discovery of tetralin carboxamide growth hormone secretagogue receptor antagonists via scaffold manipulation. J Med Chem 2004;47:6655-7
55. Abbott Laboratories, USA. Preparation of tetralin derivatives as ghrelin receptor modulators. US7115767; 2005
56. Abbott Laboratories. Preparation of diaminopyrimidines as growth hormone secretagogue receptor (GHS-R) antagonists. US 2005171131; 2005
57. Abbott Laboratories. A preparation of pyrimidine derivatives, useful as ghrelin receptor modulators. US 2005070712; 2005
58. Serby Michael D, Zhao H, Szczepankiewicz Bruce G, et al. 2,4-diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonists. J Med Chem 2006;49:2568-78
59. Xin Z, Serby Michael D, Zhao H, et al. Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists. J Med Chem 2006;49:4459-69
60. Biovitrum AB, Swed. Preparation of spiro(b-carbolinepyrrolidines) and related compounds as growth hormone secretagogue receptor (GHSR) antagonists. WO2005048916; 2005
61. Amgen Inc., USA. Preparation of benzo-fused heterocycles for treatment of obesity and eating disorders. WO2006020959; 2006
62. Elixir Pharmaceuticals, Inc., USA. Preparation of sulfonamide compounds as GHS-R modulators. WO2006135860; 2006
63. Bayer Pharmaceuticals Corporation, USA. Preparation of quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake. WO2006012577; 2006
64. Esler WP, Rudolph J, Claus TH, et al. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 2007;148:5175-85
65. Rudolph J, Esler WP, O'Connor S, et al. Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. J Med Chem 2007;50:5202-16
66. Acadia Pharmaceuticals Inc., USA. Bicyclic nitrogen compounds as modulators of ghrelin receptor and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2007079239; 2007
67. Zentaris GmbH., Germany; Le Centre Mational de la Recherche Scientifique; University of Montpeller I; University of Montpeller II. Triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors, their preparation, pharmaceutical compositions, and use in therapy. WO2007020013; 2007
68. Dainippon Sumitomo Pharma Co., Ltd., Japan. Preparation of oxindole derivatives as feeding control agents. WO2007032371; 2007
69. Merck & Co., Inc., USA. Preparation of substituted pyrazoles as ghrelin receptor antagonists. WO2008008286; 2008
70. Eli Lilly and Company, USA. Anti-human ghrelin antibodies and conjugates for diagnosis and therapy of obesity and related disorders. WO2005026211; 2005
71. Eli Lilly and Company, USA. Anti-ghrelin antibodies. WO2006019577; 2006
72. Eli Lilly and Company, USA. Humanized anti-ghrelin antibodies. WO2007101021; 2007
73. The Scripps Research Institute, USA. Vaccine immunoconjugates comprising ghrelin polypeptides for control of obesity. WO2008016976; 2008
74. Zorrilla EP, Iwasaki S, Moss JA, et al. Vaccination against weight gain. Proc Natl Acad Sci USA 2006;103:13226-31
75. Cyros Biotechnology Ag, Switz. Compositions and methods for producing ghrelin-carrier conjugates and uses as vaccines for antiobesity therapy. WO2004009124; 2004
76. Cytos Biotechnology AG., Switz. Modified ghrelin peptide-VLP (virus-like particle) carrier conjugates, and immunogenic uses for the treatment of obesity. WO2005068639; 2005
77. Cytos Biotechnology press release. Available from: http://www.cytos.com/ ?id=939
78. Boston Biomedical Research Institute, USA. Ghrelin transition state analog, antibodies and enzymes specifically bind and/or cleave octanoylated native ghrelin for suppressing appetite/hunger and treating obesity and Prader-Willi syndrome. WO2007092023; 2007
79. Noxxon Pharma A-G., Germany. Use of RNA-spiegelmers binding to n-octanoyl ghrelin for diagnosis and treatment of metabolic and cardiovascular diseases and cancer. WO2005049828; 2005
80. Noxxon Pharma A.-G., Germany; Supramol Parenteral Colloid G.m.b.H. Method for producing conjugates of polysaccharides and polynucleotides for use as drug-delivery systems. WO2005074993; 2005
81. Noxxon Pharma A.-G., Germany. Design of ribonucleic acid aptamers binding to n-octanoyl-ghrelin. WO2006108599; 2006
82. Shearman LP, Wang SP, Helmling S, et al. Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 2006;147:1517-26
83. Amylin Pharmaceuticals, Inc., USA. Methods for treating or ameliorating ghrelin-associated diseases and disorders. WO2005021026; 2005
84. Field BC, Wren AM, Cooke D, et al. Gut hormones as potential new targets for appetite regulation and the treatment of obesity. Drugs 2008;68:147-63
85. Holst B, Schwartz TW. Constitutive ghrelin receptor activity as a signaling set-point in appetite regulation. Trends Pharmacol Sci 2004;25:113-7
86. Pfluger PT, Kirchner H, Gunnel S, et al. Simultaneous deletion of ghrelin and its receptor increases motor activity and energy expenditure. Am J Physiol Gastrointest Liver Physiol 2008;294:G610-8